Next Article in Journal
Extracellular Vesicles as Transmitters of Hypoxia Tolerance in Solid Cancers
Next Article in Special Issue
Targeting Glioblastoma Stem Cells with 2-Deoxy-D-Glucose (2-DG) Potentiates Radiation-Induced Unfolded Protein Response (UPR)
Previous Article in Journal
Adjuvant Ipilimumab in High-Risk Uveal Melanoma
Previous Article in Special Issue
Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma
Open AccessReview

Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients

1
Institute of Neuroscience and Medicine (INM-3, -4, -5, -11), Forschungszentrum Juelich, 52425 Juelich, Germany
2
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
3
JARA-BRAIN-Translational Medicine, 52074 Aachen, Germany
4
Department of Neurology, RWTH Aachen University, 52074 Aachen, Germany
5
Department of Nuclear Medicine, RWTH Aachen University, 52074 Aachen, Germany
6
Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, 50937 Cologne, Germany
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(2), 153; https://doi.org/10.3390/cancers11020153
Received: 4 January 2019 / Revised: 24 January 2019 / Accepted: 25 January 2019 / Published: 29 January 2019
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
Imaging techniques such as positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable information about brain tumor patients. Particularly amino acid PET, advanced MRI techniques, and combinations thereof are of great interest for the non-invasive assessment of biological characteristics in patients with primary or secondary brain cancer. A methodological innovation that potentially advances research in patients with brain tumors is the increasing availability of hybrid PET/MRI systems, which enables the simultaneous acquisition of both imaging modalities. Furthermore, the advent of ultra-high field MRI scanners operating at magnetic field strengths of 7 T or more will allow further development of metabolic MR imaging at higher resolution. This review focuses on the combination of amino acid PET with MR spectroscopic imaging, perfusion- and diffusion-weighted imaging, as well as chemical exchange saturation transfer in patients with high-grade gliomas, especially glioblastomas. View Full-Text
Keywords: [11C]-methyl-l-methionine (MET); O-(2-[18F]-fluoroethyl)-l-tyrosine (FET); 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA); magnetic resonance spectroscopy; perfusion-weighted imaging; diffusion-weighted imaging; chemical exchange saturation transfer; brain tumors; high-grade glioma; hybrid PET/MRI scanner [11C]-methyl-l-methionine (MET); O-(2-[18F]-fluoroethyl)-l-tyrosine (FET); 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA); magnetic resonance spectroscopy; perfusion-weighted imaging; diffusion-weighted imaging; chemical exchange saturation transfer; brain tumors; high-grade glioma; hybrid PET/MRI scanner
Show Figures

Figure 1

MDPI and ACS Style

Lohmann, P.; Werner, J.-M.; Shah, N.J.; Fink, G.R.; Langen, K.-J.; Galldiks, N. Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients. Cancers 2019, 11, 153.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop